Trial Profile
An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 (Ezabenlimab) Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs BI 836880 (Primary) ; Ezabenlimab (Primary) ; Miptenalimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 04 Sep 2023 Planned End Date changed from 31 May 2024 to 28 Jun 2024.
- 04 Sep 2023 Planned primary completion date changed from 31 May 2024 to 28 Jun 2024.
- 28 Nov 2022 Planned End Date changed from 31 May 2023 to 31 May 2024.